Drilldown: Medicines

Bisoprolol (1) · Khat (1) · Nebivolol (1) · Tea (1) · Testosterone (1)

''Camellia sinensis'' (formerly ''Thea sinensis'') (1) · ''Catha edulis''. Chat, qat, the Flower of Paradise (1) · AndroGel, Testim, Axiron, Fortesta (gels); Androderm (patch); Aveed (IM); Striant (buccal); Natesto (nasal); Jatenzo, Tlando (oral undecanoate) (1) · Bystolic (1) · Zebeta (1)

Androgen / Anabolic Steroid (1) · Beta Blocker (2) · Caffeine plant (1) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · Cathinone source (1) · Excitantia (2) · Plant Medicine (2)

Caffeine + theophylline + L-theanine. L-theanine (an amino acid unique to tea) modulates glutamate and produces an 'alpha-wave' calming overlay on caffeine's stimulation, hence tea's reputation as a 'cleaner' stimulant than coffee. (1) · Endogenous androgen binding to androgen receptors; mediates male secondary sex characteristics, anabolism, libido, erythropoiesis, and CNS effects on mood/energy/aggression. Aromatized peripherally to estradiol; reduced to DHT. (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · Primary alkaloid is (S)-(-)-cathinone, a phenylpropanolamine close kin to amphetamine. Releases dopamine and norepinephrine. Also contains cathine (=norpseudoephedrine) and norephedrine. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1)

'"`UNIQ--vote-00000008-QINU`"', '"`UNIQ--vote-00000009-QINU`"' (1) · '"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) · '"`UNIQ--vote-00000747-QINU`"', '"`UNIQ--vote-00000748-QINU`"' (1) · '"`UNIQ--vote-00000758-QINU`"', '"`UNIQ--vote-00000759-QINU`"', '"`UNIQ--vote-0000075A-QINU`"' (1)

2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 5 mg daily (1) · A ''marduuf'' bundle (~50 g fresh leaves) chewed over a couple of hours (1) · Formulation-dependent. Gels: 40–50 mg topically daily. Cypionate/enanthate IM: 50–100 mg weekly. Undecanoate IM: 750 mg q10w. Patch: 4 mg/d. (1) · One cup (~40–60 mg caffeine; about half of brewed coffee) (1)

2.5, 5, 10, 20 mg tabs (1) · 5, 10 mg tabs (1) · Dried leaves, infused. Six major processings: white, green, yellow, oolong, black, pu-erh (1) · Fresh leaves and tender twigs chewed; degrades on drying (1) · Gels, patches, IM cypionate/enanthate/undecanoate, buccal tabs, nasal gel, oral undecanoate, subcutaneous pellets (1)

None (2) · 20 mg/d (1) · 40 mg/d (1) · Formulation-dependent (1)

buccal (1) · IM (1) · nasal (1) · Oral (3) · Oral (buccal absorption) (1) · oral (undecanoate only) (1) · Topical (gel/patch) (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 h (2) · 2–4 h (1) · 3–4 h (1) · Hours (nasal); ~24 h (gel/patch); 1–2 weeks (cypionate/enanthate IM); ~10 weeks (undecanoate IM) (1)

None (1) · 9–12 h (1) · Highly variable by formulation; native T is hours (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~5 h (caffeine) (1)

None (2) · Oral non-undecanoate has essentially zero bioavailability (hepatic first-pass) (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~90% (low first-pass) (1)

None (2) · Category C (2) · Category X, contraindicated; teratogenic (virilization of female fetus) (1)

None (1) · Rx-only in US (2) · Schedule I in US since 1993 (despite traditional use elsewhere); legal in Ethiopia, Kenya, Yemen, Somalia, Djibouti (1) · Schedule III (DEA, US) (1)